![]() |
JOURNAL TOOLS |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |

YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEW
Minerva Biotecnologica 2018 March;30(1):29-35
DOI: 10.23736/S1120-4826.17.02306-0
Copyright © 2017 EDIZIONI MINERVA MEDICA
language: English
Role of serum hepatitis B core-related antigen in chronic hepatitis B infection
Gian P. CAVIGLIA 1 ✉, Daniele NOVIELLO 1, Rinaldo PELLICANO 2, Antonella OLIVERO 1
1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Unit of Gastroenterology, Molinette-SGAS Hospital, Turin, Italy
Hepatitis B core-related antigen (HBcrAg) is a novel serum marker consisting of hepatitis B core antigen, hepatitis e antigen (HBeAg) and a 22 kDa precore protein without C-terminal arginine rich domain. All these core-related proteins can be simultaneously detected in serum and quantified by chemiluminescence enzyme immunoassay. Current available data indicate that HBcrAg serum levels vary according to the different phases of chronic hepatitis B (CHB) infection showing a strong correlation with both serum HBV DNA and intrahepatic HBV covalently closed circular DNA (cccDNA). In addition, HBcrAg levels seem able to identify CHB patients likely to respond to interferon-based therapy and those treated with nucleos(t)ide analogues that have higher possibility of successful treatment cessation. Finally, recent data pointed out an association between HBcrAg levels and hepatocellular carcinoma (HCC) development and recurrence. In this review we report and discuss novel findings and clinical applications of HBcrAg determination in patients with chronic hepatitis B virus infection.
KEY WORDS: Biomarkers - Hepatitis B virus - Carcinoma, hepatocellular